Cancer stem cells in relation to treatment

Norikatsu Miyoshi, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalReview article

Abstract

The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models. However, a specific signature of cell surface proteins that can identify cancer stem cells has not been developed for many solid tumors. In this review, we summarize a new technique for identifying and quantifying cancer stem cells in situ, which could be a valuable technique for evaluating the effects of therapies on this cell population. Finally, we conclude by discussing several preclinical treatment strategies that either reprogram cancer stem cells or cause them to be specifically attacked by immune cells. In summary, therapeutic and diagnostic methodologies that can attack and quantify cancer stem cells, respectively, will be valuable tools for eradicating cancer.

Original languageEnglish
Pages (from-to)232-237
Number of pages6
JournalJapanese journal of clinical oncology
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 1 2019
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Neoplasms
Therapeutics
Membrane Proteins
Population
Cell- and Tissue-Based Therapy
Radiotherapy
Stem Cells
Animal Models
Transplantation
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Cancer stem cells in relation to treatment. / Miyoshi, Norikatsu; Mizushima, Tsunekazu; Doki, Yuichiro; Mori, Masaki.

In: Japanese journal of clinical oncology, Vol. 49, No. 3, 01.03.2019, p. 232-237.

Research output: Contribution to journalReview article

Miyoshi, Norikatsu ; Mizushima, Tsunekazu ; Doki, Yuichiro ; Mori, Masaki. / Cancer stem cells in relation to treatment. In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 3. pp. 232-237.
@article{ac61f467ed60492c9d7001f9cff63dcc,
title = "Cancer stem cells in relation to treatment",
abstract = "The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models. However, a specific signature of cell surface proteins that can identify cancer stem cells has not been developed for many solid tumors. In this review, we summarize a new technique for identifying and quantifying cancer stem cells in situ, which could be a valuable technique for evaluating the effects of therapies on this cell population. Finally, we conclude by discussing several preclinical treatment strategies that either reprogram cancer stem cells or cause them to be specifically attacked by immune cells. In summary, therapeutic and diagnostic methodologies that can attack and quantify cancer stem cells, respectively, will be valuable tools for eradicating cancer.",
author = "Norikatsu Miyoshi and Tsunekazu Mizushima and Yuichiro Doki and Masaki Mori",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/jjco/hyy186",
language = "English",
volume = "49",
pages = "232--237",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Cancer stem cells in relation to treatment

AU - Miyoshi, Norikatsu

AU - Mizushima, Tsunekazu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models. However, a specific signature of cell surface proteins that can identify cancer stem cells has not been developed for many solid tumors. In this review, we summarize a new technique for identifying and quantifying cancer stem cells in situ, which could be a valuable technique for evaluating the effects of therapies on this cell population. Finally, we conclude by discussing several preclinical treatment strategies that either reprogram cancer stem cells or cause them to be specifically attacked by immune cells. In summary, therapeutic and diagnostic methodologies that can attack and quantify cancer stem cells, respectively, will be valuable tools for eradicating cancer.

AB - The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models. However, a specific signature of cell surface proteins that can identify cancer stem cells has not been developed for many solid tumors. In this review, we summarize a new technique for identifying and quantifying cancer stem cells in situ, which could be a valuable technique for evaluating the effects of therapies on this cell population. Finally, we conclude by discussing several preclinical treatment strategies that either reprogram cancer stem cells or cause them to be specifically attacked by immune cells. In summary, therapeutic and diagnostic methodologies that can attack and quantify cancer stem cells, respectively, will be valuable tools for eradicating cancer.

UR - http://www.scopus.com/inward/record.url?scp=85063944019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063944019&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy186

DO - 10.1093/jjco/hyy186

M3 - Review article

VL - 49

SP - 232

EP - 237

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -